Literature DB >> 26083764

Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial.

Robert J Mentz1,2, Marco Metra3, Gad Cotter4, Olga Milo4, Colleen McKendry2, Karen Chiswell2, Beth A Davison4, John G F Cleland5, Daniel M Bloomfield6, Howard C Dittrich7, Mona Fiuzat1,2, Piotr Ponikowski8, Michael M Givertz9, Adriaan A Voors10, John R Teerlink11, Christopher M O'Connor1,2.   

Abstract

BACKGROUND: Worsening heart failure (WHF) symptoms despite initial therapy during admission for acute heart failure (AHF) is associated with worse outcomes. The association between the time of the WHF event and the intensity of WHF therapy with outcomes is unknown. METHODS AND
RESULTS: In the PROTECT trial of 2033 AHF patients, we investigated the association between time of occurrence of WHF and intensity of therapy, with subsequent outcomes. WHF was defined by standardized, physician-determined assessment. Early WHF was defined as occurring on days 2-3 and late on days 4-7. Low intensity included restarting/increasing diuretics or vasodilators and high intensity included initiation of inotropes, vasopressors, inodilators, or mechanical support. Outcomes were death or cardiovascular/renal hospitalization over 60 days and death over 180 days. Of the 1879 patients with complete follow-up after day 7, 12.7% (n = 238) experienced WHF: 47.9% early and 52.1% late. Treatment intensity was low in 72.3% and high in 24.8% (2.9% missing). After adjusting for baseline predictors of outcome, WHF was associated with a trend toward increased 60-day death or cardiovascular/renal hospitalization [hazard ratio (HR) 1.26; 95% confidence interval (CI) 0.99-1.60; P = 0.063] and increased 180-day death (HR 1.77; 95% CI 1.33-2.34; P < 0.001). There was no evidence of a differential association between the time of occurrence of WHF and outcomes. High-intensity therapy was not significantly associated with increased event rates (180-day mortality: HR 1.44; 95% CI 0.80-2.59 vs. low).
CONCLUSIONS: Inhospital WHF was associated with increased 180-day death. The time of occurrence and intensity of WHF therapy may provide less prognostic information than whether or not WHF occurred.
© 2015 The Authors. European Journal of Heart Failure © 2015 European Society of Cardiology.

Entities:  

Keywords:  Acute heart failure; Intensity; Outcomes; Timing; Worsening heart failure

Mesh:

Substances:

Year:  2015        PMID: 26083764      PMCID: PMC5687792          DOI: 10.1002/ejhf.308

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  15 in total

1.  The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction.

Authors:  Christopher M O'Connor; Robert J Mentz; Gad Cotter; Marco Metra; John G Cleland; Beth A Davison; Michael M Givertz; George A Mansoor; Piotr Ponikowski; John R Teerlink; Adriaan A Voors; Mona Fiuzat; Daniel Wojdyla; Karen Chiswell; Barry M Massie
Journal:  Eur J Heart Fail       Date:  2012-04-25       Impact factor: 15.534

2.  Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.

Authors:  Michael S Cuffe; Robert M Califf; Kirkwood F Adams; Raymond Benza; Robert Bourge; Wilson S Colucci; Barry M Massie; Christopher M O'Connor; Ileana Pina; Rebecca Quigg; Marc A Silver; Mihai Gheorghiade
Journal:  JAMA       Date:  2002-03-27       Impact factor: 56.272

3.  Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.

Authors:  John R Teerlink; Gad Cotter; Beth A Davison; G Michael Felker; Gerasimos Filippatos; Barry H Greenberg; Piotr Ponikowski; Elaine Unemori; Adriaan A Voors; Kirkwood F Adams; Maria I Dorobantu; Liliana R Grinfeld; Guillaume Jondeau; Alon Marmor; Josep Masip; Peter S Pang; Karl Werdan; Sam L Teichman; Angelo Trapani; Christopher A Bush; Rajnish Saini; Christoph Schumacher; Thomas M Severin; Marco Metra
Journal:  Lancet       Date:  2012-11-07       Impact factor: 79.321

4.  Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.

Authors:  Marco Metra; Gad Cotter; Beth A Davison; G Michael Felker; Gerasimos Filippatos; Barry H Greenberg; Piotr Ponikowski; Elaine Unemori; Adriaan A Voors; Kirkwood F Adams; Maria I Dorobantu; Liliana Grinfeld; Guillaume Jondeau; Alon Marmor; Josep Masip; Peter S Pang; Karl Werdan; Margaret F Prescott; Christopher Edwards; Sam L Teichman; Angelo Trapani; Christopher A Bush; Rajnish Saini; Christoph Schumacher; Thomas Severin; John R Teerlink
Journal:  J Am Coll Cardiol       Date:  2013-01-15       Impact factor: 24.094

5.  Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study.

Authors:  Gad Cotter; Marco Metra; Beth A Davison; Stefanie Senger; Robert C Bourge; John G F Cleland; Guillaume Jondeau; Henry Krum; Christopher M O'Connor; John D Parker; Guillermo Torre-Amione; Dirk J van Veldhuisen; Olga Milo; Isaac Kobrin; Maurizio Rainisio; John J V McMurray; John R Teerlink
Journal:  Eur J Heart Fail       Date:  2014-11-05       Impact factor: 15.534

6.  International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial.

Authors:  Robert J Mentz; Gad Cotter; John G F Cleland; Susanna R Stevens; Karen Chiswell; Beth A Davison; John R Teerlink; Marco Metra; Adriaan A Voors; Liliana Grinfeld; Mikhail Ruda; Viacheslav Mareev; Chaim Lotan; Daniel M Bloomfield; Mona Fiuzat; Michael M Givertz; Piotr Ponikowski; Barry M Massie; Christopher M O'Connor
Journal:  Eur J Heart Fail       Date:  2014-04-25       Impact factor: 15.534

7.  Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.

Authors:  John J V McMurray; John R Teerlink; Gadi Cotter; Robert C Bourge; John G F Cleland; Guillaume Jondeau; Henry Krum; Marco Metra; Christopher M O'Connor; John D Parker; Guillermo Torre-Amione; Dirk J van Veldhuisen; Jim Lewsey; Aline Frey; Maurizio Rainisio; Isaac Kobrin
Journal:  JAMA       Date:  2007-11-07       Impact factor: 56.272

8.  Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure--association with signs and symptoms, hospitalization duration, and 60-day outcomes.

Authors:  Gad Cotter; Marco Metra; Beth Davison Weatherley; Howard C Dittrich; Barry M Massie; Piotr Ponikowski; Daniel M Bloomfield; Christopher M O'Connor
Journal:  Cardiology       Date:  2009-10-20       Impact factor: 1.869

9.  Early worsening heart failure in patients admitted with acute heart failure--a new outcome measure associated with long-term prognosis?

Authors:  Beth Davison Weatherley; Olga Milo-Cotter; G Michael Felker; Nir Uriel; Edo Kaluski; Zvi Vered; Christopher M O'Connor; Kirkwood F Adams; Gad Cotter
Journal:  Fundam Clin Pharmacol       Date:  2009-07-28       Impact factor: 2.748

10.  In-hospital worsening heart failure and associations with mortality, readmission, and healthcare utilization.

Authors:  Adam D DeVore; Bradley G Hammill; Puza P Sharma; Laura G Qualls; Robert J Mentz; Katherine Waltman Johnson; Gregg C Fonarow; Lesley H Curtis; Adrian F Hernandez
Journal:  J Am Heart Assoc       Date:  2014-07-11       Impact factor: 5.501

View more
  7 in total

1.  Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF.

Authors:  Marat Fudim; Christopher M O'Connor; Allison Dunning; Andrew P Ambrosy; Paul W Armstrong; Adrian Coles; Justin A Ezekowitz; Stephen J Greene; Marco Metra; Randall C Starling; Adriaan A Voors; Adrian F Hernandez; G Michael Felker; Robert J Mentz
Journal:  Eur J Heart Fail       Date:  2017-10-29       Impact factor: 15.534

Review 2.  The Impact of Worsening Heart Failure in the United States.

Authors:  Lauren B Cooper; Adam D DeVore; G Michael Felker
Journal:  Heart Fail Clin       Date:  2015-08-11       Impact factor: 3.179

3.  Apelin ameliorated acute heart failure via inhibiting endoplasmic reticulum stress in rabbits.

Authors:  Yanqing Li; Haohan Lu; Wenyuan Xu; Yuxuan Shang; Cece Zhao; Yipu Wang; Rui Yang; Sheng Jin; Yuming Wu; Xiaoning Wang; Xu Teng
Journal:  Amino Acids       Date:  2021-02-20       Impact factor: 3.520

4.  Differences in health care use and outcomes by the timing of in-hospital worsening heart failure.

Authors:  Lauren B Cooper; Bradley G Hammill; Puza P Sharma; Adam D DeVore; Robert J Mentz; Gregg C Fonarow; Peter S Pang; Lesley H Curtis; Adrian F Hernandez
Journal:  Am Heart J       Date:  2015-09-11       Impact factor: 4.749

5.  Implications of Using Different Definitions on Outcomes in Worsening Heart Failure.

Authors:  Jacob P Kelly; Lauren B Cooper; Dianne Gallup; Kevin J Anstrom; Horng H Chen; Margaret M Redfield; Christopher M O'Connor; Robert J Mentz; Adrian F Hernanadez; G Michael Felker
Journal:  Circ Heart Fail       Date:  2016-08       Impact factor: 8.790

6.  Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study.

Authors:  John R Teerlink; Adriaan A Voors; Piotr Ponikowski; Peter S Pang; Barry H Greenberg; Gerasimos Filippatos; G Michael Felker; Beth A Davison; Gad Cotter; Claudio Gimpelewicz; Leandro Boer-Martins; Margaret Wernsing; Tsushung A Hua; Thomas Severin; Marco Metra
Journal:  Eur J Heart Fail       Date:  2017-04-28       Impact factor: 15.534

Review 7.  In-hospital worsening heart failure: a clinically relevant endpoint?

Authors:  Andrew L Clark; Myriam Cherif; Theresa A McDonagh; Iain B Squire
Journal:  ESC Heart Fail       Date:  2017-07-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.